Filing Flows › Xeris Biopharma Holdings (XERS) › Q2 2026 › vs Q1 2026
Xeris Biopharma Holdings (XERS) Q2 2026 vs Q1 2026 (quarter over quarter)
Xeris Biopharma Holdings's revenue rose $9.0M (+11%) from $83.1M in Q1 2026 to $92.1M in Q2 2026. The biggest changes: Product revenue, net +$8.6M (+10%); Royalty, contract and other revenue +$423K (+63%).
Xeris Biopharma Holdings, Q2 2026: revenue $92.1M (+29% year over year), operating margin 5.6%, net loss $31.1M, operating cash flow $8.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Recorlev | $56.8M | $49.8M | $7.0M | +14% |
| Gvoke | $22.5M | $20.8M | $1.7M | +8% |
| Keveyis | $11.7M | $11.9M | −$211K | -2% |
| Product revenue, net | $91.0M | $82.5M | $8.6M | +10% |
| Royalty, contract and other revenue | $1.1M | $673K | $423K | +63% |
| Revenue | $92.1M | $83.1M | $9.0M | +11% |
| Net loss | $31.1M | −$2.2M | $33.3M | — |
| Costs & expenses | $123M | $83.1M | $40.1M | +48% |
| Operating costs | $86.9M | $75.2M | $11.7M | +16% |
| Interest & other, net | $36.3M | $5.7M | $30.6M | +538% |
| Cost of revenue | $12.5M | $10.6M | $1.9M | +18% |
| Research & development | $10.7M | $8.8M | $1.9M | +21% |
| SG&A | $61.0M | $53.1M | $7.9M | +15% |
| Other operating costs | $2.7M | $2.7M | $1K | 0% |
| Operating cash sources | $39.4M | $7.6M | $31.7M | +416% |
| Depreciation & amortization | $323K | $337K | −$14K | -4% |
| Share-based compensation | $11.1M | $4.1M | $6.9M | +167% |
| Working capital & other | $28.0M | $3.2M | $24.8M | +786% |
| Net loss absorbed | $31.1M | −$2.2M | $33.3M | — |
| Operating cash flow | $8.3M | $9.9M | −$1.6M | -16% |
Questions
How much did Xeris Biopharma Holdings's revenue grow quarter over quarter in Q2 2026?
Xeris Biopharma Holdings's revenue rose $9.0M (+11%) from $83.1M in Q1 2026 to $92.1M in Q2 2026.
What drove Xeris Biopharma Holdings's revenue change in Q2 2026?
Product revenue, net +$8.6M (+10%); Royalty, contract and other revenue +$423K (+63%).